---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-034082"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2026-05-12T20:03:05+00:00"
generated_at: "2026-05-12T20:06:25.969584+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M

## Summary
- Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
- Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.
- Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.
- 2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.
- Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky.

## SEC filing metadata
- accession: 0001628280-26-034082
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2026-05-12T20:03:05+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/0001628280-26-034082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/tlsi-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-034082
- JSON: https://secwatch.observer/filing/0001628280-26-034082.json
- Plain text: https://secwatch.observer/filing/0001628280-26-034082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.